257 related articles for article (PubMed ID: 36401046)
21. Celecoxib treatment improves muscle function in mdx mice and increases utrophin A expression.
Péladeau C; Adam NJ; Jasmin BJ
FASEB J; 2018 Sep; 32(9):5090-5103. PubMed ID: 29723037
[TBL] [Abstract][Full Text] [Related]
22. Microutrophin expression in dystrophic mice displays myofiber type differences in therapeutic effects.
Banks GB; Chamberlain JS; Odom GL
PLoS Genet; 2020 Nov; 16(11):e1009179. PubMed ID: 33175853
[TBL] [Abstract][Full Text] [Related]
23. Sertoli Cells Improve Myogenic Differentiation, Reduce Fibrogenic Markers, and Induce Utrophin Expression in Human DMD Myoblasts.
Salvadori L; Chiappalupi S; Arato I; Mancuso F; Calvitti M; Marchetti MC; Riuzzi F; Calafiore R; Luca G; Sorci G
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680138
[TBL] [Abstract][Full Text] [Related]
24. Nitric oxide and l-arginine cause an accumulation of utrophin at the sarcolemma: a possible compensation for dystrophin loss in Duchenne muscular dystrophy.
Chaubourt E; Fossier P; Baux G; Leprince C; Israël M; De La Porte S
Neurobiol Dis; 1999 Dec; 6(6):499-507. PubMed ID: 10600405
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological prospects in the treatment of Duchenne muscular dystrophy.
Ruegg UT
Curr Opin Neurol; 2013 Oct; 26(5):577-84. PubMed ID: 23995279
[TBL] [Abstract][Full Text] [Related]
26. Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice.
Ebihara S; Guibinga GH; Gilbert R; Nalbantoglu J; Massie B; Karpati G; Petrof BJ
Physiol Genomics; 2000 Sep; 3(3):133-44. PubMed ID: 11015608
[TBL] [Abstract][Full Text] [Related]
27. Mimicking sarcolemmal damage
Tejedera-Villafranca A; Montolio M; Ramón-Azcón J; Fernández-Costa JM
Biofabrication; 2023 Sep; 15(4):. PubMed ID: 37725998
[TBL] [Abstract][Full Text] [Related]
28. Stabilization of the cardiac sarcolemma by sarcospan rescues DMD-associated cardiomyopathy.
Parvatiyar MS; Brownstein AJ; Kanashiro-Takeuchi RM; Collado JR; Dieseldorff Jones KM; Gopal J; Hammond KG; Marshall JL; Ferrel A; Beedle AM; Chamberlain JS; Renato Pinto J; Crosbie RH
JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31039133
[TBL] [Abstract][Full Text] [Related]
29. Promising therapeutic approaches of utrophin replacing dystrophin in the treatment of Duchenne muscular dystrophy.
Wu R; Song Y; Wu S; Chen Y
Fundam Res; 2022 Nov; 2(6):885-893. PubMed ID: 38933385
[TBL] [Abstract][Full Text] [Related]
30. Repression of phosphatidylinositol transfer protein α ameliorates the pathology of Duchenne muscular dystrophy.
Vieira NM; Spinazzola JM; Alexander MS; Moreira YB; Kawahara G; Gibbs DE; Mead LC; Verjovski-Almeida S; Zatz M; Kunkel LM
Proc Natl Acad Sci U S A; 2017 Jun; 114(23):6080-6085. PubMed ID: 28533404
[TBL] [Abstract][Full Text] [Related]
31. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
32. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice.
Odom GL; Gregorevic P; Allen JM; Finn E; Chamberlain JS
Mol Ther; 2008 Sep; 16(9):1539-45. PubMed ID: 18665159
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-6 and neuregulin-1 as regulators of utrophin expression via the activation of NRG-1/ErbB signaling pathway in mdx cells.
Juretić N; Díaz J; Romero F; González G; Jaimovich E; Riveros N
Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):770-780. PubMed ID: 27988307
[TBL] [Abstract][Full Text] [Related]
34. Utrophin influences mitochondrial pathology and oxidative stress in dystrophic muscle.
Kennedy TL; Moir L; Hemming S; Edwards B; Squire S; Davies K; Guiraud S
Skelet Muscle; 2017 Oct; 7(1):22. PubMed ID: 29065908
[TBL] [Abstract][Full Text] [Related]
35. Upregulation of brain utrophin does not rescue behavioral alterations in dystrophin-deficient mice.
Perronnet C; Chagneau C; Le Blanc P; Samson-Desvignes N; Mornet D; Laroche S; De La Porte S; Vaillend C
Hum Mol Genet; 2012 May; 21(10):2263-76. PubMed ID: 22343141
[TBL] [Abstract][Full Text] [Related]
36. Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice.
Burkin DJ; Wallace GQ; Nicol KJ; Kaufman DJ; Kaufman SJ
J Cell Biol; 2001 Mar; 152(6):1207-18. PubMed ID: 11257121
[TBL] [Abstract][Full Text] [Related]
37. Inactivation of Sirt6 ameliorates muscular dystrophy in mdx mice by releasing suppression of utrophin expression.
Georgieva AM; Guo X; Bartkuhn M; Günther S; Künne C; Smolka C; Atzberger A; Gärtner U; Mamchaoui K; Bober E; Zhou Y; Yuan X; Braun T
Nat Commun; 2022 Jul; 13(1):4184. PubMed ID: 35859073
[TBL] [Abstract][Full Text] [Related]
38. Utility of dystrophin and utrophin staining in childhood muscular dystrophy.
Sundaram C; Vydehi B; Meena K; Murthy J
Indian J Pathol Microbiol; 2004 Jul; 47(3):367-9. PubMed ID: 16295426
[TBL] [Abstract][Full Text] [Related]
39. Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review.
Szwec S; Kapłucha Z; Chamberlain JS; Konieczny P
BioDrugs; 2024 Jan; 38(1):95-119. PubMed ID: 37917377
[TBL] [Abstract][Full Text] [Related]
40. Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models.
van der Pijl EM; van Putten M; Niks EH; Verschuuren JJ; Aartsma-Rus A; Plomp JJ
Eur J Neurosci; 2016 Jun; 43(12):1623-35. PubMed ID: 27037492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
